A 41-year-old Dunwoody mom who never smoked a day in her life was diagnosed with terminal stage 4 lung cancer.

A fundraiser for a rare genetic form of lung cancer happened Sunday, raising money for greater research and awareness of the ...

Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication. Alecensa ...

An isogenic cell line was created to model cancer ... ALK. We employed the CRISPR/Cas9 genome editing platform for the generation of the desired targeted genomic rearrangement in the A549 lung ...

Alectinib is recommended, within its marketing authorisation, as an option for the adjuvant treatment of stage 1B (tumours 4 cm or larger) to 3A ALK-positive non-small-cell lung cancer (NSCLC) after ...

The FDA has approved Roche’s Alecensa for the treatment of early stage resected non-small cell lung cancer, or NSCLC ... makes Alecensa the first and only ALK inhibitor therapy approved for ...

At CREST in 2007, Professor Mano discovered the EML4-ALK fusion gene; at Research Acceleration in 2012, he discovered the RET and ROSI fusion genes, which are all responsible for causing lung cancer.

Research collaborators at the Rogel Cancer Center’s Judith Tam ALK Lung Cancer Research Initiative presented positive preclinical data reporting that Reqorsa induced apoptosis in alectinib ...

Alectinib (Alecensa) is available on the NHS. It is a possible adjuvant treatment for stage 1B (tumours 4 cm or larger) to 3A ALK-positive non-small-cell lung cancer (NSCLC) after surgery in adults.